November 1, 2017 / 10:58 PM / a year ago

Teva wins court decision nixing Bayer patent on ED drug Staxyn

A federal appeals court on Wednesday invalidated a Bayer AG patent on its erectile dysfunction treatment Staxyn, clearing the way for Teva Pharmaceutical Industries Ltd to launch a generic version of the drug.

The U.S. Court of Appeals for the Federal Circuit reversed a lower court decision in finding invalid on obviousness grounds a Bayer patent relating to Staxyn’s formulation that expires in 2028.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below